Molecular Diagnostics
Recent Advances in the Fast-Growing Molecular Diagnostics Industry
| Price: £999.00 Approx $1,490.71 (USD) €1,117.13 (EUR) |
|
|---|---|
| Overview: | |
| Molecular diagnostics (MDx) is becoming increasingly entwined with the development of pharmaceutical drugs. Initially, it was used in clinical settings to aid diagnosis, prognosis, and optimal treatment, but now, backed by regulatory authorities, it is becoming important in the development and commercialization of new and existing therapies. As a result, the MDx industry, already a multibillion-dollar market, will continue to expand at a significant pace. |
|
|
This paper is available from one of our partner sites.
Click here for details and to download it. |
|
By Dr CL Barton / Publication Date: 16th March 2007
Contents:
Biomarkers and Diagnostics
Molecular Diagnostics
Executive Summary.3
Strategic Considerations 3
Stakeholder Implications 3
Overview4
The Evolution of the MDx Industry 4
The Three Phases of the MDx Industry 5
Phase One: Infectious Diseases 5
Phase Two: Blood Screening 6
Phase Three: Pharmacogenomic Testing, Genetic Testing, Predictive Testing, and
Companion Diagnostics 6
Pharmacogenomic Testing 7
Predictive Testing 10
Genetic Testing 11
Expert Commentary–MDx: Looking Ahead 12
Companion Diagnostics 14
MDx Technologies and Platforms 14
MDx Technologies 14
PCR 14
DNA Methylation 15
RNA Interference17
MDx Platforms 17
Microarrays and Nanoarrays 17
Microfl uidics 18
Multiplex Assays18
Changing Trends 18
Pharmaceutical/MDx Alliances and Acquisitions 18
Support from Regulatory Authorities 19
Alliances Between Diagnostics and Technology-Based Companies 19
Regulatory Environment and Advances in MDx 20
Key Players in the MDx Field 21
Roche Diagnostics 21
Abbott Diagnostics 21
Bayer Diagnostics/Siemens Medical Solutions Group 22
Market Outlook 23
List of Tables:
Tables:
1. Select Molecular Diagnostics for Infectious Agents6
2. The Third Phase of the MDx Industry 7
3. Recent Alliances Between Research Organizations and Pharmaceutical/Biotech
Companies 8
4. AmpliChip CYP450 Test 10
5. Select PGx-Based Diagnostic Tests 11
6. Comparison of Molecular Tests 16
7. Select Pharma-Diagnostics Industry Alliances 21
8. Recent Alliances Between Diagnostic and Technology Companies 22
9. Key Mergers and Acquisitions in the MDx Market 23
10. Likely Impact of Increased Uptake of MDx Tests 25
11. Global Market Opportunities for Molecular Diagnostics, 2005-2010 26
Figures:
1. The Three Phases of the Molecular Diagnostic Industry 5
2. Growth in Alliances Between Academia/Research Organizations and Pharmaceutical/Biotech
Companies, 2002-2006 10
3. Select Molecular Diagnostic Technologies and Platforms 15
4. Interrelationship Between Pharmaceutical/Biotech and Molecular Diagnostics Companies 19
5. Future Diversifi cation of the MDx Market 26